Fig. 1.

Criteria for enrollment of patients in the study. *Patients for whom the therapeutic drug could be confirmed, or patients with SBP of 140 mmHg or higher and DBP of 90 mmHg or higher for ≥2 days, with reference to WHO hypertension criteria. ^†Patients for whom the therapeutic drug could be confirmed. ^‡Patients with changes in ST segment of 0.1 mV or more (including a decrease in ST segment by 0.05 mV or more in a Master 2-step test), an abnormal Q wave, negative T wave, U wave, or other abnormal findings related to ischemic changes on the ECG in a resting state or after exercise; or patients with LVH, abnormal wall movement, or a right ventricular/right atrial load on echocardiography in a test performed within 1 month of surgery. ^§Patients with an abnormal change (≥0.1 mV) in ST segment from the value on ECG at rest and with an ST segment of ≥+0.1 mV or ≤−0.1 mV. ^║Variation in HR immediately before administration is less than 10 % of that recorded 1 or 3 min earlier. DBP diastolic blood pressure, ECG electrocardiogram, HR heart rate, LVH left ventricular hypertrophy, SBP systolic blood pressure